UK Medtechs Look Beyond Brexit To Long-Term Life-Science Strategy

The UK medtech industry is looking past Brexit to a time when the government's new Life Science Strategy has gone live. It also seeks better access to the NHS for medtech companies developing and launching innovations as the UK makes its own way in the world as a former EU member state.

Brexit is not quite the done deal, even if the impetus towards it seems all but unstoppable. Seen through this lens, the UK medtech industry association, ABHI, sees little merit in analyzing the potential benefits and drawbacks of the UK's decision to leave the EU. Rather, it prefers now to get on with helping to shape the post-Brexit landscape for the UK medtech industry.

The perfect opportunity arose on Jan. 23 after UK Prime Minister Theresa May launched proposals for a modern "Industrial Strategy"...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United Kingdom

More from Europe

NHS Orders Halt On Unapproved AI Scribes, Vendors Rush To Self-Certify

 

NHS England's national chief clinical information officer issued a cease and desist on unapproved ambient voice technology and AI scribes. The move caused confusion among AVT vendors and went beyond joint MHRA/NHS guidance. IMed consultant Ben Austin shares his perspective.

EU/US Trade Deal Raises Questions For Medtech

 

There is still no clarity on how life sciences will be treated in the final agreement.

NICE To Consult On UK Late-Stage Healthtech Assessments

 
• By 

NICE’s three-pronged lifecycle approach to healthtech evaluations includes late-stage assessments (LSA), which will be the focus of a short consultation in August.